Yumanity Therapeutics
790 Memorial Drive, Suite 2C
Cambridge
Massachusetts
02139
United States
Tel: 617-409-5300
Website: http://yumanity.com/
Email: info@yumanity.com
About Yumanity Therapeutics
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the estimated patient population of 50 million people worldwide, this remains an area of tremendous unmet medical need with no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address illnesses such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company’s approach concentrates on correcting the cellular pathologies driven by misfolded proteins and the altered biology and phenotypes driving these diseases.
66 articles about Yumanity Therapeutics
-
Yumanity Therapeutics to Present at Multiple Upcoming November Investor Conferences
11/16/2021
Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will be presenting at the following investor conferences in November.
-
Yumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
11/15/2021
Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced financial results for the third quarter ended September 30, 2021 and provided an overview of the Company’s recent corporate developments and upcoming milestones.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 12, 2021
11/12/2021
Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced the grant to two employees of non-statutory stock options for the purchase of up to an aggregate of 2,000 shares of Yumanity’s common stock.
-
Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson’s Disease; Company Plans to Advance Program to Phase 2
11/10/2021
Yumanity Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease.
-
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 14, 2021
10/14/2021
Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced the grant to an employee of non-statutory stock options for the purchase of up to an aggregate of 4,000 shares of Yumanity’s common stock.
-
Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference
9/9/2021
Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 23rd Global Investment Conference.
-
Yumanity Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sep 09, 2021
9/9/2021
Yumanity Therapeutics announced the grant to one new employee of a non-statutory stock option for the purchase of up to an aggregate of 30,000 shares of Yumanity’s common stock.
-
Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants
8/16/2021
Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced the appointment of Michael D. Wyzga as Senior Vice President, Chief Financial Officer.
-
Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
8/12/2021
Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2021, and provided an overview of the Company’s recent corporate developments and upcoming milestones.
-
Yumanity Therapeutics to Present at the BTIG Virtual Biotechnology Conference
8/6/2021
Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced that Company management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021, at 1:00 p.m. ET.
-
Yumanity Therapeutics Appoints Devin W. Smith as General Counsel
6/14/2021
Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced the appointment of Devin W. Smith as Senior Vice President and General Counsel.
-
Yumanity Therapeutics to Present at Upcoming Virtual Investor Conferences - May 27, 2021
5/27/2021
Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the following virtual investor conferences in June.
-
Yumanity Therapeutics’ R&D Day Reviews Near-Term Value Drivers and Pipeline-Generating Discovery Engine
5/17/2021
initiation of a window of opportunity study of an SCD (stearoyl-CoA desaturase) inhibitor in glioblastoma multiforme patients in early 2022
-
Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments
5/13/2021
Demonstrated lead program YMTX-7739 inhibits novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson’s disease
-
Yumanity Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference
5/12/2021
Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. EDT.
-
Yumanity Therapeutics to Host Virtual R&D Day on Monday, May 17, 2021
5/4/2021
Yumanity Therapeutics, a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, announced that the Company will host a virtual R&D Day on Monday, May 17, 2021 at 12:00 p.m. ET.
-
Yumanity Therapeutics to Present at the 2021 B. Riley Securities’ Neuroscience Conference
4/28/2021
Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the 2021 B. Riley Securities’ Neuroscience Conference.
-
Yumanity Therapeutics’ YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy Volunteers
4/22/2021
YTX-7739 is Yumanity’s lead product candidate in clinical development for the treatment of Parkinson’s disease
-
Yumanity Therapeutics Appoints Neuroscience Drug Development Veteran, Ajay Verma, M.D., Ph.D., Executive Vice President, Head of Research & Development
4/13/2021
Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Ajay Verma, M.D., Ph.D., as Executive Vice President, Head of Research & Development